$0.86
2.43%
Nasdaq, Jul 03, 10:50 pm CET
ISIN
US59564R2031
Symbol
BDRX
Sector
Industry

Midatech Pharma Plc Sponsored ADR Stock price

$0.86
-0.30 25.98% 1M
-3.64 80.92% 6M
-3.19 78.80% YTD
-21.38 96.14% 1Y
-21,999.14 100.00% 3Y
-54,799.14 100.00% 5Y
-14,699,999.14 100.00% 10Y
-14,699,999.14 100.00% 20Y
Nasdaq, Closing price Thu, Jul 03 2025
-0.02 2.43%
ISIN
US59564R2031
Symbol
BDRX
Sector
Industry

Key metrics

Basic
Market capitalization
$570.0k
Enterprise Value
$-720.0k
Net debt
positive
Cash
$2.3m
Shares outstanding
267.4m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.0
P/B
20.2
Financial Health
Equity Ratio
56.3%
Return on Equity
-68.8%
ROCE
-94.4%
ROIC
-88.5%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-12.2m | -
EBIT
$-12.6m | $-18.8m
Net Income
$-7.8m | $-953.5m
Free Cash Flow
$-17.8m
Growth (TTM | estimate)
Revenue
-100.0% | -
EBITDA
-15.7% | -
EBIT
-14.8%
Net Income
19.0% | -12,093.2%
Free Cash Flow
-83.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$0.0
FCF per Share
$-0.1
Short interest
3.5%
Employees
13
Rev per Employee
$0.0
Show more

Is Midatech Pharma Plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Midatech Pharma Plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Midatech Pharma Plc Sponsored ADR forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Midatech Pharma Plc Sponsored ADR forecast:

Buy
86%
Hold
14%

Financial data from Midatech Pharma Plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.18 5.18
13% 13%
-
- Research and Development Expense 7.42 7.42
34% 34%
-
-12 -12
16% 16%
-
- Depreciation and Amortization 0.35 0.35
10% 10%
-
EBIT (Operating Income) EBIT -13 -13
15% 15%
-
Net Profit -7.82 -7.82
19% 19%
-

In millions USD.

Don't miss a Thing! We will send you all news about Midatech Pharma Plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Midatech Pharma Plc Sponsored ADR Stock News

Neutral
GlobeNewsWire
10 days ago
June 27, 2023 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that at its Annual General Meeting held yesterday, all resolutions put to the Company's shareh...
Neutral
GlobeNewsWire
12 days ago
June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce the activation of ...
Neutral
GlobeNewsWire
14 days ago
June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce it has selected Serenta as the bra...
More Midatech Pharma Plc Sponsored ADR News

Company Profile

Midatech Pharma Plc commercializes oncology treatments and cancer supportive care products through its U.S. commercial organization, Midatech Pharma US. The company engages in the development of pharmaceutical products utilizing its nanomedicine and sustained release technologies. Its pipeline includes MTD119, MTX102, MTD201 and MTX110. Midatech Pharma was founded on September 12, 2014 and is headquartered in Cardiff, the United Kingdom.

Head office United Kingdom
CEO Stephen Stamp
Employees 13
Founded 2000
Website www.biodexapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today